GLUE
GLUE
$10.66
+9.45% 2026-10-19
Sector n/a
GLUESPY
1W
+1.3%
1M
-12.1%
3M
-54.6%
6M
-46.2%
YTD
-32.0%
1Y
+6.1%
Grades vs sector
Momentumno data–
Momentum
no data
Percentile within its GICS sector across the S&P 1500.
Growthno data–
Growth
no data
Percentile within its GICS sector across the S&P 1500.
Valueno data–
Value
no data
Percentile within its GICS sector across the S&P 1500.
Profitabilityno data–
Profitability
no data
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap–
P/E (trailing)–
P/E (forward)–
52-week range– – –
Revenue growth (YoY, latest qtr)–
Dividend yield–
Analyst consensus–
Mean price target–
Valuation & fundamentals
Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
•Piotroski F-score5/9
Discounted cash flow
Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Quality & financial health
Gross margin
–
Operating margin
-633.0%
FCF margin
-111.7%
Net margin
-560.9%
Return on equity
-33.1%
Return on invested capital
-36.2%
Net debt / EBITDA
–
Current ratio
10.6×
Interest cover
–
Cash conversion (OCF/NI)
–
Piotroski F-score 5/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved
Analysts
No analyst targets available.
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $123.7M | $-38.6M | $-27.5M |
| 2024 | $75.6M | $-72.7M | $38.0M |
| 2023 | $0 | $-135.4M | $-62.8M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
Next report: 2026-11-05 · before open · EPS est -0.20
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.37 | -0.43 | -17.6% |
| 2026-05-07 | -0.38 | -0.45 | -19.1% |
| 2026-03-17 | -0.34 | -0.55 | -63.4% |
| 2025-11-06 | -0.35 | -0.33 | +6.4% |
| 2025-08-07 | -0.38 | -0.15 | +60.2% |
| 2025-05-08 | -0.32 | 0.57 | +277.0% |
| 2025-03-20 | 0.03 | 0.27 | +902.6% |
| 2024-11-07 | -0.47 | -0.29 | +38.4% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $9.0M | -61.3% |
| 2026-03-31 | $4.2M | – |
| 2025-12-31 | $2.8M | – |
| 2025-09-30 | $12.8M | – |
| 2025-06-30 | $23.2M | – |
Insider trades
Bowen Matthew
$137
Principal Accounting Officer · 2026-10-05
SELL$137
News
AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases
PR Newswire · Oct 13
UBS Adjusts Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Buy Rating
MT Newswires · Oct 12
Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
MarketBeat · Oct 06
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 02
Sector Update: Healthcare Stocks Decline Premarket Thursday
MT Newswires · Oct 01
Kleo Kolor Launches New Glue-On Gel Line, Bringing 3D Nail Art With Salon-Level Artistry To Your Fingers in Minutes
PR Newswire · Oct 01
Sector Update: Healthcare
MT Newswires · Oct 01
Monte Rosa Therapeutics Says MRT-8102 Showed Biomarker Improvements in Phase 1 Study
MT Newswires · Oct 01
Stats refreshed 2026-10-19 19:03:10 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.